TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 28589618

Group type: EXPERIMENTAL
Intervention: Pimecrolimus cream 1% twice daily for 2 weeks, then moisturizer cream twice daily for 2 weeks
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Pimecrolimus cream 1% twice daily for 2 weeks, then once daily for another 2 weeks
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Pimecrolimus cream 1% twice daily for 4 weeks
Number of subjects: 30

Group type: COMPARATOR
Intervention: All groups
Number of subjects: 30
Study: 27888594

Group type: EXPERIMENTAL
Intervention: 90 dBA noise exposure for 20 minutes
Number of subjects: 100

Group type: COMPARATOR
Intervention: Non-exposed control group
Number of subjects: 100
Study: 24662224

Group type: EXPERIMENTAL
Intervention: Aerobic Interval Training (AIT)
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Nonlinear Resistance Training (NRT)
Number of subjects: 34
Study: 22343272

Group type: EXPERIMENTAL
Intervention: Combined counseling and disability evaluation
Number of subjects: 506

Group type: COMPARATOR
Intervention: Disability evaluation
Number of subjects: 506
Study: 20067513

Group type: COMPARATOR
Intervention: Fluvastatin 80 mg alone
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Fluvastatin 80 mg plus Ezetimibe 10 mg
Number of subjects: 90
Study: 18753727

Group type: EXPERIMENTAL
Intervention: Combination therapy with amiodarone (100-200 mg/day) and enalapril (5 mg/day)
Number of subjects: 58

Group type: COMPARATOR
Intervention: Amiodarone alone
Number of subjects: 58
Study: 16299015

Group type: EXPERIMENTAL
Intervention: Experimental treatments
Number of subjects: 36567

Group type: COMPARATOR
Intervention: Standard treatments
Number of subjects: 36567
Study: 12207166

Group type: EXPERIMENTAL
Intervention: Iodized oil (200 mg iodine)
Number of subjects: 214
Study: 10678693

Group type: EXPERIMENTAL
Intervention: Dominant meanings of the target words
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Subordinate meanings of the target words
Number of subjects: 0

Group type: COMPARATOR
Intervention: Contextual sentences (dominant or subordinate meaning)
Number of subjects: 0
Study: 9105549

Group type: EXPERIMENTAL
Intervention: Cefodizime 1 g b.i.d. (median 7 days) in study A
Number of subjects: 74

Group type: EXPERIMENTAL
Intervention: Cefodizime 2 g once daily (median 6 days) in study B
Number of subjects: 74
Study: 7831435

Group type: EXPERIMENTAL
Intervention: Lorazepam (2 mg)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 3532749

Group type: EXPERIMENTAL
Intervention: Nitrendipine
Number of subjects: 63

Group type: COMPARATOR
Intervention: Hydrochlorothiazide
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: Nitrendipine + Hydrochlorothiazide
Number of subjects: 63
Study: 29752907

Group type: EXPERIMENTAL
Intervention: Pilates group (PG)
Number of subjects: 64

Group type: COMPARATOR
Intervention: Control group (CG)
Number of subjects: 64
Study: 27782821

Group type: EXPERIMENTAL
Intervention: ICF intervention and microscopy-based TB diagnostic algorithm in cohort A
Number of subjects: 10131

Group type: EXPERIMENTAL
Intervention: ICF intervention and Xpert-based TB diagnostic algorithm in cohort B
Number of subjects: 10131

Group type: COMPARATOR
Intervention: Cohort R (retrospective cohort)
Number of subjects: 10131

Group type: EXPERIMENTAL
Intervention: Cohort B (Xpert-based)
Number of subjects: 10131
Study: 26281475

Group type: EXPERIMENTAL
Intervention: Baseline gamma-glutamyltransferase (GGT)
Number of subjects: 537

Group type: EXPERIMENTAL
Intervention: Baseline fasting plasma glucose (FPG) and GGT
Number of subjects: 537

Group type: EXPERIMENTAL
Intervention: 2 hr plasma glucose (2 hr PG)
Number of subjects: 537

Group type: EXPERIMENTAL
Intervention: HbA1c
Number of subjects: 537

Group type: EXPERIMENTAL
Intervention: Baseline GGT
Number of subjects: 537
Study: 22085427

Group type: EXPERIMENTAL
Intervention: rmhTNF‐α plus standard chemotherapies
Number of subjects: 190

Group type: COMPARATOR
Intervention: Standard chemotherapies alone
Number of subjects: 190

Group type: EXPERIMENTAL
Intervention: rmhTNF‐α plus standard chemotherapies (specifically in lung cancer)
Number of subjects: 190

Group type: EXPERIMENTAL
Intervention: rmhTNF‐α
Number of subjects: 190

Group type: COMPARATOR
Intervention: rmhTNF‐α plus standard chemotherapies vs standard chemotherapies alone
Number of subjects: 190
Study: 20110397

Group type: EXPERIMENTAL
Intervention: Budesonide/formoterol maintenance and reliever therapy
Number of subjects: 8188
Study: 18273633

Group type: EXPERIMENTAL
Intervention: SmartCranks
Number of subjects: 20

Group type: COMPARATOR
Intervention: Conventional cranks
Number of subjects: 20
Study: 15883432

Group type: EXPERIMENTAL
Intervention: Boiled and mashed orange-fleshed sweet potato (OFSP), 125 g daily for 53 school days, providing 1031 retinol activity equivalents/d as beta-carotene.
Number of subjects: 180

Group type: COMPARATOR
Intervention: Control group consumed an equal amount of white-fleshed sweet potato devoid of beta-carotene for 53 school days.
Number of subjects: 180
Study: 12522373

Group type: EXPERIMENTAL
Intervention: Infliximab 5 or 10 mg/kg
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 11022632

Group type: EXPERIMENTAL
Intervention: Nutrition education programme undertaken by 6 trained local women (nutrition advisers) in the SA.
Number of subjects: 1263
Study: 8790023

Group type: EXPERIMENTAL
Intervention: Lamifiban (1, 2, 4, or 5 micrograms/min)
Number of subjects: 365

Group type: EXPERIMENTAL
Intervention: Lamifiban (high doses)
Number of subjects: 365

Group type: EXPERIMENTAL
Intervention: Lamifiban (highest dose)
Number of subjects: 365

Group type: EXPERIMENTAL
Intervention: Lamifiban (all doses)
Number of subjects: 365

Group type: EXPERIMENTAL
Intervention: Lamifiban
Number of subjects: 365

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 365
Study: 31451419

Group type: EXPERIMENTAL
Intervention: Contact precautions in a single-bed room
Number of subjects: 463

Group type: COMPARATOR
Intervention: Contact precautions in a multiple-bed room
Number of subjects: 463
Study: 30199881

Group type: EXPERIMENTAL
Intervention: Informed consent
Number of subjects: 1319

Group type: EXPERIMENTAL
Intervention: Opt-out plus
Number of subjects: 1319

Group type: COMPARATOR
Intervention: Opt-out
Number of subjects: 1319
Study: 27407053

Group type: EXPERIMENTAL
Intervention: 2 g of extended-release niacin with 40 mg of laropiprant daily
Number of subjects: 25673

Group type: COMPARATOR
Intervention: Matching placebo
Number of subjects: 25673
Study: 24703531

Group type: EXPERIMENTAL
Intervention: Intermittent cetuximab
Number of subjects: 169

Group type: COMPARATOR
Intervention: Continuous cetuximab
Number of subjects: 169
Study: 22823075

Group type: EXPERIMENTAL
Intervention: Heavy exercise (40-min submaximal incremental test followed by 90-min continuous exercise at 50% of maximal aerobic power-output and a 1-h rest period)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Light exercise (40-min submaximal incremental test followed by a 2.5-h rest period)
Number of subjects: 15
Study: 18703165

Group type: EXPERIMENTAL
Intervention: 2004 articles reporting full CONSORT pre-randomization information
Number of subjects: 480

Group type: EXPERIMENTAL
Intervention: 2006 articles reporting full CONSORT pre-randomization information
Number of subjects: 480
Study: 16313988

Group type: EXPERIMENTAL
Intervention: Arteriorvenous cerebral transit time (cTT)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: P3a latency
Number of subjects: 30
Study: 14520516

Group type: EXPERIMENTAL
Intervention: Hydroxyethyl starch (n = 6)
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Human albumin (n = 6)
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Polygeline (n = 9)
Number of subjects: 21
Study: 11037739

Group type: EXPERIMENTAL
Intervention: 5‐isosorbide‐mononitrate (5‐ISMN) 30 mg three times daily for 7 days
Number of subjects: 11

Group type: COMPARATOR
Intervention: Intravenous infusion of glyceryl trinitrate for 20 minutes
Number of subjects: 11
Study: 9354191

Group type: EXPERIMENTAL
Intervention: Oral 5-ASA 3 g/day
Number of subjects: 117

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 117
Study: 8247308

Group type: EXPERIMENTAL
Intervention: Nicardipine Retard (40 mg twice a day)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Placebo (twice a day)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Nicardipine Retard
Number of subjects: 36

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study: 2880810

Group type: EXPERIMENTAL
Intervention: Nadolol + HCTZ 50 mg b.i.d.
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Propranolol + HCTZ 50 mg b.i.d.
Number of subjects: 22

Group type: COMPARATOR
Intervention: HCTZ 50 mg b.i.d. + placebo
Number of subjects: 22
Study: 30286851

Group type: EXPERIMENTAL
Intervention: Oxycodone (OXY) 5 mg
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: Ibuprofen (IBU) 600 mg
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: Acetaminophen (ACE) 500 mg
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: Oxycodone (OXY) 5 mg (Open CTR group)
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: Ibuprofen (IBU) 600 mg (Open CTR group)
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: Acetaminophen (ACE) 500 mg (Open CTR group)
Number of subjects: 105
Study: 26813970

Group type: EXPERIMENTAL
Intervention: Serum glycan profiles determined by mass spectrometry in NSCLC cases
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Combination marker including serum glycan profiles
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Four glycan variables combined with pro-SFTPB
Number of subjects: 100
Study: 24777164

Group type: EXPERIMENTAL
Intervention: Digital Rectal Evacuation (DE)
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Transanal Irrigation (TAI) with 500 ml
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Filling Cystometry (FC)
Number of subjects: 11
Study: 22406126

Group type: EXPERIMENTAL
Intervention: Senofilcon A (ACUVUE® OASYS® with HYDRACLEAR® Plus) worn on a daily wear basis and replaced every 2 weeks
Number of subjects: 90
Study: 20169196

Group type: EXPERIMENTAL
Intervention: Blocked condition (PD patients)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Blocked condition (Controls)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Random condition (Both groups)
Number of subjects: 20
Study: 18390450

Group type: EXPERIMENTAL
Intervention: Group A (FDCs)
Number of subjects: 293

Group type: EXPERIMENTAL
Intervention: Group B (FDCs)
Number of subjects: 293

Group type: COMPARATOR
Intervention: Group C (single drug formulations)
Number of subjects: 293
Study: 16418753

Group type: EXPERIMENTAL
Intervention: Atomoxetine (n=12)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo (n=14)
Number of subjects: 30
Study: 12740074

Group type: EXPERIMENTAL
Intervention: Maize/soya‐based flour containing amylase
Number of subjects: 80

Group type: COMPARATOR
Intervention: Maize/soya‐based flour without amylase (Control)
Number of subjects: 80
Study: 10988131

Group type: EXPERIMENTAL
Intervention: Continuous positive airway pressure (CPAP)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Oxygen only (Control)
Number of subjects: 30
Study: 8782022

Group type: EXPERIMENTAL
Intervention: Wooden backboard
Number of subjects: 37

Group type: COMPARATOR
Intervention: Vacuum mattress-splint (VMS)
Number of subjects: 37
Study: 1615966

Group type: EXPERIMENTAL
Intervention: Fresh sperm
Number of subjects: 57

Group type: COMPARATOR
Intervention: Frozen sperm
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: Fresh cervical cap insemination
Number of subjects: 57

Group type: COMPARATOR
Intervention: Frozen cervical cap insemination
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: Fresh intrauterine insemination
Number of subjects: 57

Group type: COMPARATOR
Intervention: Frozen intrauterine insemination
Number of subjects: 57
Study: 6547101

Group type: EXPERIMENTAL
Intervention: Day Nurse (single dose)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 29031239

Group type: EXPERIMENTAL
Intervention: Probiotic group (Bifidobacterium animalis subsp. lactis BB‐12 and Lactobacillus rhamnosus GG)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group (placebo lozenges)
Number of subjects: 60
Study: 27708111

Group type: EXPERIMENTAL
Intervention: Zofenopril 60 mg plus acetylsalicylic acid (ASA) 100 mg
Number of subjects: 716

Group type: COMPARATOR
Intervention: Ramipril 10 mg plus ASA
Number of subjects: 716
Study: 23602325

Group type: EXPERIMENTAL
Intervention: Acupressure wristbands
Number of subjects: 500

Group type: EXPERIMENTAL
Intervention: Sham acupressure wristbands
Number of subjects: 500

Group type: COMPARATOR
Intervention: Antiemetics alone
Number of subjects: 500
Study: 23747777

Group type: EXPERIMENTAL
Intervention: Rivaroxaban (a factor Xa inhibitor)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard therapy (dual antiplatelet therapy)
Number of subjects: 0
Study: 20839431

Group type: EXPERIMENTAL
Intervention: Open reduction combined with internal fixation (n=35)
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: Artificial radial head replacement (n=30)
Number of subjects: 65
Study: 17375118

Group type: EXPERIMENTAL
Intervention: Virgin olive oil (50 ml daily)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Refined olive oil (control)
Number of subjects: 28
Study: 16399150

Group type: EXPERIMENTAL
Intervention: Etanercept 50 mg twice-weekly
Number of subjects: 618

Group type: EXPERIMENTAL
Intervention: Etanercept
Number of subjects: 618

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 618
Study: 14581118

Group type: EXPERIMENTAL
Intervention: 1 microg/kg fentanyl intravenously
Number of subjects: 28

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 28
Study: 10737480

Group type: EXPERIMENTAL
Intervention: BCG maintenance therapy (intravesical and percutaneous BCG each week for 3 weeks at 3, 6, 12, 18, 24, 30, and 36 months)
Number of subjects: 384

Group type: COMPARATOR
Intervention: No BCG maintenance therapy
Number of subjects: 384

Group type: EXPERIMENTAL
Intervention: BCG maintenance therapy
Number of subjects: 384
Study: 8762313

Group type: EXPERIMENTAL
Intervention: Unipolar diathermy technique
Number of subjects: 105

Group type: COMPARATOR
Intervention: Ligation technique
Number of subjects: 105
Study: 1578910

Group type: EXPERIMENTAL
Intervention: Intensive consolidation therapy (including allogeneic and autologous bone marrow transplantation)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Autologous bone marrow transplantation
Number of subjects: 0

Group type: COMPARATOR
Intervention: High-dose cytarabine (3 gm/M2/day IV on days 1-6)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Conventional induction therapy +/− GM-CSF
Number of subjects: 0
Study: 2860167

Group type: EXPERIMENTAL
Intervention: Daily antiseptic mouthwash with chlorhexidine‐gluconate
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Daily antiseptic mouthwash with povidone‐iodine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Hygienic treatment alone
Number of subjects: 0
Study: 31179831

Group type: EXPERIMENTAL
Intervention: Levothyroxine (20 μg bolus followed by 20 μg/h infusion)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo (identically appearing)
Number of subjects: 24
Study: 28393440

Group type: EXPERIMENTAL
Intervention: Immediate Intervention Group (IIG)
Number of subjects: 77

Group type: COMPARATOR
Intervention: Delayed Intervention Group (DIG)
Number of subjects: 77
Study: 26488141

Group type: EXPERIMENTAL
Intervention: Curriculum-based advocacy training
Number of subjects: 257

Group type: COMPARATOR
Intervention: Self-directed advocacy activities
Number of subjects: 257

Group type: EXPERIMENTAL
Intervention: Combined groups (curriculum and self-directed)
Number of subjects: 257
Study: 23759472

Group type: EXPERIMENTAL
Intervention: Rivaroxaban
Number of subjects: 9248

Group type: COMPARATOR
Intervention: Warfarin
Number of subjects: 9248
Study: 21816692

Group type: EXPERIMENTAL
Intervention: Home-based physical exercise program (aerobic and anaerobic exercises)
Number of subjects: 84

Group type: COMPARATOR
Intervention: Conventional treatment for diabetes
Number of subjects: 84
Study: 19539306

Group type: EXPERIMENTAL
Intervention: Morphological derivations with stress changes
Number of subjects: 104

Group type: EXPERIMENTAL
Intervention: Prosodic sensitivity and morphological awareness
Number of subjects: 104
Study: 16458200

Group type: EXPERIMENTAL
Intervention: Ascorbic acid supplementation (500 mg, twice daily; 2 weeks)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Ascorbic acid supplementation
Number of subjects: 24
Study: 15566336

Group type: EXPERIMENTAL
Intervention: Group counseling (2 sessions at about 2 months postpartum)
Number of subjects: 162

Group type: COMPARATOR
Intervention: Control group (no group counseling)
Number of subjects: 162
Study: 11710662

Group type: EXPERIMENTAL
Intervention: Nasal strip
Number of subjects: 14

Group type: COMPARATOR
Intervention: Control
Number of subjects: 14

Group type: COMPARATOR
Intervention: Placebo nasal strip
Number of subjects: 14
Study: 9213203

Group type: EXPERIMENTAL
Intervention: bisoprolol (10 mg q.d.)
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: lisinopril (20 mg q.d.)
Number of subjects: 105
Study: 10779310

Group type: EXPERIMENTAL
Intervention: 0.05 mg/m2 rIFN-gamma
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: rIFN-gamma
Number of subjects: 20

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 20
Study: 3315914

Group type: EXPERIMENTAL
Intervention: oral ketanserin (20 mg X 7)
Number of subjects: 6

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 6
Study: 29148822

Group type: EXPERIMENTAL
Intervention: Galactagogue (GG) containing Sylimarin-Phosphatidylserine and Galega
Number of subjects: 100

Group type: COMPARATOR
Intervention: Placebo (PG)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Galactagogue (GG)
Number of subjects: 100
Study: 27132409

Group type: EXPERIMENTAL
Intervention: DermoXEN Ultracalming Special for diabetics
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: DermoXEN Vitexyl vaginal gel
Number of subjects: 48

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 48
Study: 24604487

Group type: EXPERIMENTAL
Intervention: Shared care model of follow-up visits in the first 12 months after treatment, including a survivorship care plan, GP management guidelines, register and recall systems, screening for distress and unmet needs, and patient information resources.
Number of subjects: 90

Group type: COMPARATOR
Intervention: Current hospital follow-up care (Control group).
Number of subjects: 90
Study: 23690424

Group type: EXPERIMENTAL
Intervention: Cetuximab plus brivanib 800 mg orally daily
Number of subjects: 750

Group type: COMPARATOR
Intervention: Cetuximab plus placebo
Number of subjects: 750
Study: 20626735

Group type: EXPERIMENTAL
Intervention: Ondansetron
Number of subjects: 34

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 34
Study: 18400707

Group type: EXPERIMENTAL
Intervention: MUFA diet (n = 16): moderate in fat (35-45% of energy) and high in monounsaturated fatty acids (> 20% of energy)
Number of subjects: 46

Group type: COMPARATOR
Intervention: Control diet (n = 12): 35% of energy as fat (> 15% of energy as saturated fatty acids)
Number of subjects: 46

Group type: COMPARATOR
Intervention: LF diet (n = 18): low-fat diet (20-30% of energy)
Number of subjects: 46
Study: 16630383

Group type: EXPERIMENTAL
Intervention: Twice-weekly iron supplementation (ferrous dextran, 60 mg elemental iron)
Number of subjects: 329

Group type: COMPARATOR
Intervention: Placebo tablet
Number of subjects: 329
Study: 14620026

Group type: EXPERIMENTAL
Intervention: Video model with visual and verbal cues
Number of subjects: 60

Group type: COMPARATOR
Intervention: Video model with visual cues
Number of subjects: 60

Group type: COMPARATOR
Intervention: Video model with verbal cues
Number of subjects: 60

Group type: COMPARATOR
Intervention: Video model only
Number of subjects: 60

Group type: COMPARATOR
Intervention: Discovery learning
Number of subjects: 60

Group type: COMPARATOR
Intervention: Verbal instruction
Number of subjects: 60
Study: 10942476

Group type: EXPERIMENTAL
Intervention: Bipolar electrocautery scissors
Number of subjects: 50

Group type: COMPARATOR
Intervention: Conventional technique
Number of subjects: 50
Study: 8911006

Group type: EXPERIMENTAL
Intervention: 500 micrograms OprI vaccine
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: 200 micrograms OprI vaccine
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: 50 micrograms OprI vaccine
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: 20 micrograms OprI vaccine
Number of subjects: 28

Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 28
Study: 1729038

Group type: COMPARATOR
Intervention: Continuous iv infusion of furosemide (initial dose 0.1 mg/kg iv, infusion rate 0.1 mg/kg.hr, doubled every 2 hrs to max 0.4 mg/kg.hr)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Intermittent iv infusion of furosemide (1 mg/kg iv every 4 hrs, increased by 0.25 mg/kg every 4 hrs to max 1.5 mg/kg)
Number of subjects: 0
Study: 6339571

Group type: EXPERIMENTAL
Intervention: Thymopoietin pentapeptide (TP-5) 50 mg, thrice-weekly injections for 6 weeks
Number of subjects: 18

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study: 31607271

Group type: EXPERIMENTAL
Intervention: Influenza vaccine (part of a randomized trial)
Number of subjects: 555

Group type: EXPERIMENTAL
Intervention: Index case age 1-4 years
Number of subjects: 555

Group type: EXPERIMENTAL
Intervention: Coinfection as initial infection
Number of subjects: 555

Group type: EXPERIMENTAL
Intervention: No electricity in household
Number of subjects: 555
Study: 28085515

Group type: EXPERIMENTAL
Intervention: PNAM
Number of subjects: 84

Group type: COMPARATOR
Intervention: Non-PNAM
Number of subjects: 84
Study: 27179726

Group type: EXPERIMENTAL
Intervention: Immediate monitoring using wearable sensors (single-lead electrocardiogram)
Number of subjects: 2100

Group type: EXPERIMENTAL
Intervention: Delayed monitoring using wearable sensors (single-lead electrocardiogram)
Number of subjects: 2100

Group type: COMPARATOR
Intervention: Observational control group (n = 4,000)
Number of subjects: 2100
Study: 25160064

Group type: EXPERIMENTAL
Intervention: Weekly standardized SMS
Number of subjects: 348

Group type: EXPERIMENTAL
Intervention: Weekly standardized supervisory visits
Number of subjects: 348

Group type: COMPARATOR
Intervention: No intervention (Control)
Number of subjects: 348
Study: 18728038

Group type: EXPERIMENTAL
Intervention: Low-dose aspirin
Number of subjects: 148

Group type: COMPARATOR
Intervention: Non-users of low-dose aspirin (Control)
Number of subjects: 148
Study: 15029508

Group type: EXPERIMENTAL
Intervention: Automated contour detection technique for tracing the lumen, outer boundary and plaque contours in carotid MR images
Number of subjects: 17
Study: 11087965

Group type: EXPERIMENTAL
Intervention: mCPP (0.5 mg/kg body weight)
Number of subjects: 34